Bristol to Seek Melanoma Approval for Opdivo Ahead of Expectations
News 07/10/2014

Bristol to Seek Melanoma Approval for Opdivo Ahead of Expectations

Bristol-Myers Squibb Co said on Thursday it plans to seek U.S. marketing approval in the third quarter for its experimental cancer immunotherapy Opdivo as a treatment for advanced melanoma, which would be months sooner than Wall Street expected. July 10, 2014

Japan Approves World’s First PD-1 Drug, Nivolumab
News 07/07/2014

Japan Approves World’s First PD-1 Drug, Nivolumab

Ono Pharmaceutical Co has become the first company in the world to get an approval for a PD-1 checkpoint inhibitor, as regulators in Japan gave the green light to nivolumab, developed with Bristol-Myers Squibb, as a treatment for melanoma. July 7, 2014

GSK Receives EU Approval For Mekinist For Melanoma
News 07/04/2014

GSK Receives EU Approval For Mekinist For Melanoma

The European Commission has granted marketing authorization for UK pharma giant GlaxoSmithKline's (LSE: GSK) Mekinist(trametinib) as a single agent in the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. July 4, 2014

Surgical Treatment For Metastatic Melanoma Of the Liver Increases Overall Survival
News 06/30/2014

Surgical Treatment For Metastatic Melanoma Of the Liver Increases Overall Survival

Surgical resection markedly improves survival among metastatic melanoma patients whose disease is isolated to a few areas in the liver, according to new study findings. June 30, 2014

Researchers Develop New Way to Combat Drug Resistance For Melanoma Patients
News 06/30/2014

Researchers Develop New Way to Combat Drug Resistance For Melanoma Patients

Moffitt Cancer Center researchers developed a new way to identify possible therapeutic targets for patients with drug resistant melanoma. June 30, 2014

More Than 40 Melanoma-specific Genes That Determine Aggressiveness Discovered
News 06/27/2014

More Than 40 Melanoma-specific Genes That Determine Aggressiveness Discovered

Researchers from the Spanish National Cancer Research Centre (CNIO) have discovered more than 40 genes that predict the level of aggressiveness of melanoma and that distinguish it from other cancers with a poor prognosis. June 27, 2014

News 06/25/2014

Frontline Nivolumab Improves Survival in Phase III Melanoma Study

Frontline treatment with the anti-PD-1 agent nivolumab significantly extended overall survival (OS) when compared with dacarbazine for patients with metastatic or unresectable melanoma, according to early phase III results released by Bristol-Myers Squibb (BMS), the company developing the drug. June 25, 2014

News 06/09/2014

Durable Response Rate of 25% With TILs in Melanoma

With all the excitement over the new immune-checkpoint inhibitor drugs in melanoma, many of which are not yet available, it's easy to overlook another immunotherapy - tumor infiltrating lymphocytes (TILs) - that has been resulting in dramatic and durable responses for some years now. June 9, 2014

News 06/02/2014

Merck & Co. Reports Promising Early-Stage Data for Pembrolizumab in Melanoma, Lung Cancer

Merck & Co. on Monday presented promising Phase Ib study data at the ASCO annual meeting for the experimental anti-PD-1 antibody pembrolizumab, also known as MK-3475, in patients with advanced melanoma and also those with PD-L1-positive, advanced non-small-cell lung cancer (NSCLC). June 2, 2014

News 05/20/2014

Older Males Have Greater Incidence of Ulceration in Melanoma

Ulcerated cutaneous melanoma occurs at a statistically significantly higher rate among men aged 40 to 84 years with deep tumors compared with different age and sex groups. May 20, 2014

Please keep me informed.

Receive comprehensive, breaking news about melanoma, research, legislation, and events.

  • This field is for validation purposes and should be left unchanged.